Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger
Microcap company Histogenics has managed to stir up a final rally around its stock before it’s relegated to the biotech history books.
Malvern, PA-based Ocugen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
